// App-Quantinova.ai

OR40-5 : Improved Oral Glucose Tolerance in Prediabetics and Type 2 Diabetics (T2D) in a Pilot Clinical Trial Testing a Novel Gastrointestinal (GI) Microbiome Modulator

Researchers

Presenter

  • Mark Louis Heiman

Principal Investigators

  • Jeffrey H Burton

  • Elena Deych

  • William D Shannon

  • Frank Lyons Greenway

Medical Centers

  • MicroBiome Therapeutics, Indianapolis, IN

  • Pennington Biomedical Research Center, Baton Rouge, LA.

  • Pennington Biomedical Research Center, Baton Rouge, LA.

  • BioRankings, LLC, St. Louis, MO

  • Washington University in St Louis, St. Louis, MO

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Type 2 diabetes mellitus

  • Dysbiosis

Biomarkers

  • Anaplastic lymphoma Kinase

  • Cluster of differentiation 79A

  • Fibroblast growth factor receptor 1

  • High sensitivity C-reactive protein

  • Insulin

Drug/Treatment

  • ghrelin

  • NM504

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved